Tianjin dev: Tianjin Lisheng Pharmaceutical's net income attributable to the parent company in the first three quarters decreased by 50.6% to 0.169 billion yuan.

Sina Hong Kong stocks · Oct 30 07:27

Tianjin dev (00882) announced that tianjin lisheng pharmaceutical, an indirectly wholly-owned subsidiary, achieved total operating income of 1.024 billion yuan (RMB, the same below) for the nine months ended September 30, 2024, a year-on-year increase of 12.3%; net income attributable to the owners of the parent company was 0.169 billion yuan, a year-on-year decrease of 50.6%; and basic earnings per share was 0.66 yuan.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

天津发展：力生制药前三季度归母净利润1.69亿元 同比下降50.6%

Tianjin dev: Tianjin Lisheng Pharmaceutical's net income attributable to the parent company in the first three quarters decreased by 50.6% to 0.169 billion yuan.

Risk Disclaimer

Statement

天津发展：力生制药前三季度归母净利润1.69亿元同比下降50.6%